Latest Oncology News

Second-Line Lisocabtagene Maraleucel Provides Benefit in Large B-Cell Lymphoma

August 10, 2022

Findings from the phase 2 PILOT study reveal lisocabtagene maraleucel to provide benefit as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation.

As Backlog of Delayed Cancer Screenings are Addressed, Inequities in Care Persist

August 10, 2022

In an interview with Targeted OncologyTM, Debra Patt, MD, PhD, MBA, FASCO, discusses the impact of delayed cancer screenings in potential patients and how the COVID-19 pandemic has increased existing inequities in cancer care.